INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4) (INTERVAL)

INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4): a Multicentre, Randomised, Controlled, Phase III Study

To determine if supervised high intensity aerobic and resistance training increases overall survival compared to self-directed exercise in patients with metastatic prostate cancer.

Study Overview

• Status: Active, not recruiting
• Conditions: Metastatic Prostate Cancer
• Intervention / Treatment: Behavioral: High intensity aerobic and resistance training; Behavioral: Psychosocial support

• Study Type: Interventional
• Enrollment (Estimated): 866
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Australia
  • Queensland
    • Brisbane, Queensland, Australia
      • Australian Prostate Cncr Research Centre
    • Brisbane, Queensland, Australia
      • University of Queensland
  • Victoria
    • Melbourne, Victoria, Australia
      • Victoria University / Sunshine Hospital
  • Western Australia
    • Perth, Western Australia, Australia
      • Edith Cowan University
• Canada
  • Montreal, Canada
    • Centre Hospitalier de l'Université de Montréal (CRCHUM)
  • Alberta
    • Edmonton, Alberta, Canada
      • University of Alberta
• Germany
  • Cologne, Germany
    • German Sport University Cologne
• Netherlands
  • Rotterdam, Netherlands
    • Erasmus MC
• United Kingdom
  • Belfast, United Kingdom
    • Queen's University Belfast
  • Glasgow, United Kingdom
    • University of Glasgow
  • London, United Kingdom
    • Kings College London
  • Surrey
    • Guildford, Surrey, United Kingdom
      • University of Surrey
• United States
  • California
    • Los Angeles, California, United States
      • Cedars Sinai Medical Centre
    • San Francisco, California, United States
      • UCSF
  • Colorado
    • Denver, Colorado, United States
      • UC Denver
  • Minnesota
    • Mineapolis, Minnesota, United States
      • University of Minnesota
  • Oregon
    • Portland, Oregon, United States
      • Oregon Health & Science University
  • Washington
    • Seattle, Washington, United States
      • Fred Hutchinson Cancer Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

mCRPC status:

• mCRPC patients defined as; adenocarcinoma of the prostate with systemic metastatic disease despite castrate levels of testosterone (<50 ng/dL) due to orchiectomy or LHRH agonist.

  o Patients must have one or more of the following to be considered mCRPC

• Metastatic Disease Progression: >20% increase in the sum of diameters of measurable lesions from the time of maximal regression or appearance of one or more new lesions.
• Bone Scan Progression: Appearance of one or more new lesions on bone scan attributable to prostate cancer.
• PSA Progression: PSA ≥2 ng/ml that has risen serially on at least two occasions, each at least one week apart (PSA1 < PSA2 < PSA3).
• PSMA PET/CT scan progression: Appearance of one or more new lesions on PSMA PET/CT scan attributable to prostate cancer.

• At enrolment, mCRPC patients must fit into one of the following 5 categories:

  1. Treatment naïve for mCRPC (have not yet started approved therapies for CRPC ie: Abiraterone/Enzalutamide/Apalutamide / or Docetaxel, Cabazitaxel or other approved first line chemotherapy; less than 4 weeks on approved therapies is still considered to be treatment naïve) Or
  2. Receiving Abi/Enza/Apa for mCRPC AND responding or stable (PSA values must be stable or declining after at least 4 weeks since starting Abi/Enza/Apa for mCRPC) Or
  3. Patients with PSA progression while on Abi/Enza/Apa are eligible as long as they are asymptomatic AND there is no intent on starting chemotherapy within 6 months Or
  4. Patients treated with Docetaxel, Cabazitaxel or other approved first line chemotherapy as first line for mCRPC who are asymptomatic without ANY evidence of progression Or

  5. Patients may have progressed following first line Docetaxel, Cabazitaxel or other first line chemotherapy and are now receiving treatment with Abi/Enza/Apa. These patients must absolutely be responding or stable (PSA values must be stable or declining after starting Abi/Enza/Apa treatment) and have an estimated life expectancy of more than 1 year.

     mHSPC Status:

• mHSPC patients must be classified as either high-risk or high-volume mHSPC. These groups are defined as adenocarcinoma of the prostate with systemic metastatic disease and patients also fit into one of the following 2 categories: 6. High-risk: defined as having at least 2 of three criteria: (i) Gleason score ≥8, (ii) presence of ≥3 lesions on bone scan, or (iii) presence of INTERVAL Protocol Version 5.0, 19 August 2019 4 measurable visceral lesions (PSMA PET imaging should not be used in the definition of high-risk disease) Or 7. High-volume: defined as having the presence of visceral metastases and/or ≥ four bone metastases with at least one outside of the vertebral column and pelvis (PSMA PET imaging should not be used in the definition of high-volume disease)

Additional criteria for all groups:

• All patients will be required to be on ADT during the study period or have had a prior bilateral orchiectomy.
• Men with small cell neuroendocrine tumours or features of small cell disease are not eligible.
• ≥4 weeks since last major surgery and fully recovered.
• No known contraindications to high intensity exercise, including, but not limited to: brain metastases; current congestive heart failure (New York Heart Association Class II, III or IV); serious or non-healing wound, ulcer, or bone fracture; spinal cord compromise or instrumentation due to metastatic disease; peripheral neuropathy ≥grade 3. No serious cardiovascular events within 12 months including, but not limited to, transient ischemic attack (TIA), cerebrovascular accident (CVA), or myocardial infarction (MI). Patients with a history of hypertension must be well-controlled (< 160/90) on anti-hypertensive therapy.
• Halabi Nomogram score <1951 (Risk Category rated as low or intermediate risk)
• Age ≥18 years
• Required Baseline Laboratory Values: ANC ≥ 1500/uL; Platelet count ≥ 100,000/uL; Creatinine ≤ 1.5 x upper limits of normal; Bilirubin ≤ 1.5 x upper limits of normal; AST ≤ 1.5 x upper limits of normal; Serum testosterone ≤ 50 ng/dL
• ECOG performance status 0-1
• Medical clearance by treating physician to undergo a symptom-limited cardiopulmonary exercise test and vigorous aerobic and resistance exercise training, and able to complete an acceptable cardiopulmonary exercise test.
• Exercise Coordination Centre (ECC) review and approval of subject's screening bone scan / areas with bone metastases.
• Men participating in vigorous aerobic exercise for >60 min/week or structured resistance exercise ≥2 days/week, are not eligible.
• Subject is willing and able to use technological aspects of the trial.
• The subject is fluent in the language as designated by the institution at which he would be enrolled.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Arm A: Supervised exercise group; Supervised high intensity aerobic and resistance exercise tapering to self management with psychosocial support	Behavioral: High intensity aerobic and resistance training; Behavioral: Psychosocial support
Other: Arm B: Self directed exercise group; Self directed exercise and psychosocial support group	Behavioral: Psychosocial support

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival	Overall survival will be measured from the time of randomization until death	up to 5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disease Progression	Time to disease progression will be measured from randomization until the first of the following: first CT or bone scan documenting disease progression, initiation of a new therapy for mPC (clinical progression), or first occurrence of a Symptomatic Skeletal Related Event (SSE).	up to 5 years
Symptomatic Skeletal Related Events (SSE)	Time to first occurrence of SSE will be defined as the time from randomization to documentation of any of the following (whichever occurs first) + 1 day: Use of external beam radiation therapy to relieve bone pain; Occurrence of new symptomatic pathological bone fractures that may be vertebral or non-vertebral. Asymptomatic compression fractures detected by radiology review only will not be considered a SSE.; Spinal cord compression; Change in antineoplastic therapy to treat bone pain; Surgical intervention to treat bone pain	up to 5 years
Opiate Use	Opiate use will be assessed via BPI-SF, the medical record review at entry with a lead-in period (<28 days). The questionnaires will be administered every three cycles until month 24, and in month 36.	up to 5 years
Analgesic Use	Analgesic use will be assessed via BPI-SF, the World Health Organisation (WHO) analgesic scale, and medical record review at entry with a lead-in period (<28 days). The WHO analgesic scale will be completed every three cycles (based on medical review) and questionnaires will be administered every three cycles until month 24, and in month 36.	up to 5 years
Biomarker analysis	Inflammatory and cytokine systemic milieu	up to 5 years
Biomarker analysis	Insulin/Glucose Metabolism	up to 5 years
Biomarker analysis	Androgen biosynthesis	up to 5 years
Quality of Life	Physical and emotional quality of life measured by the questionnaires- Functional Assessment of Cancer Therapy- Prostate (FACT-P), Functional assessment of Chronic Illness Therapy (FACIT-Fatigue), and EuroQOL Five Dimension Questionnaire (EQ5D) will be assessed every 3 cycles.	up to 5 years
Physical Function	Physical function will be assessed using strength assessments (1RM), a cardiopulmonary exercise test (CPET) and a functional performance test (400m walk)	up to 5 years
Pain	Pain will be assessed via questionnaire Brief Pain Inventory- short form (BPI-SF) and medical record review at entry with a lead-in period (<28 days) and repeated measures will occur every three cycles	up to 5 years

Collaborators and Investigators

• Sponsor: Movember Foundation
• Collaborators: King's College London; Centre hospitalier de l'Université de Montréal (CHUM); University of California, San Francisco; Edith Cowan University
• Investigators: Study Chair: Robert Newton, Edith Cowan University; Study Chair: Fred Saad, Centre hospitalier de l'Université de Montréal (CHUM)

Publications and helpful links

General Publications

• Newton RU, Kenfield SA, Hart NH, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci L, Plymate SR, Praet SFE, Guinan EM, Van Blarigan EL, Casey O, Buzza M, Gledhill S, Zhang L, Galvao DA, Ryan CJ, Saad F. Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open. 2018 May 14;8(5):e022899. doi: 10.1136/bmjopen-2018-022899.

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2016
• Primary Completion (Estimated): October 1, 2025
• Study Completion (Estimated): October 1, 2026

Study Registration Dates

• First Submitted: March 10, 2016
• First Submitted That Met QC Criteria: March 31, 2016
• First Posted (Estimated): April 6, 2016

Study Record Updates

• Last Update Posted (Actual): November 27, 2024
• Last Update Submitted That Met QC Criteria: November 24, 2024
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Keywords: Exercise; Prostate cancer; Metastatic; Hormone sensitive; Castrate resistant
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Prostatic Neoplasms
• Other Study ID Numbers: GAP4

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No